Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug vedotin plus individualized radiotherapy in low-risk HPV-positive oropharyngeal carcinoma (Phase II)
ChiCTR2600122233Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of becotatug vedotin in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ChiCTR2600122233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122233.